Prolong Pharmaceuticals

📍 South Plainfield, United States🗓 Founded 2005👥 20 employees💰 Last funded 2019
Pharmaceutical Manufacturing🌐 prolongpharma.com
Website LinkedIn
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The companys lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2005
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Prolong Pharmaceuticals?
Prolong Pharmaceuticals has 1 investors on record on gritt.io.
When did Prolong Pharmaceuticals last raise funding?
The most recent investment in Prolong Pharmaceuticals recorded on gritt.io was in 2019.
When was Prolong Pharmaceuticals founded?
Prolong Pharmaceuticals was founded in 2005.
What industry is Prolong Pharmaceuticals in?
Prolong Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Prolong Pharmaceuticals based?
Prolong Pharmaceuticals is headquartered in South Plainfield, United States.